We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current ZVRA market cap is 414.73M. The company's latest EPS is USD -0.8627 and P/E is -9.01.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 2.9M | 13.22M | 3.43M | 4.45M | 3.7M |
| Operating Income | -15.36M | -14.67M | -20.49M | -23.8M | -27.31M |
| Net Income | -14.05M | -15.15M | -16.62M | -19.93M | -33.23M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 12.84M | 13.29M | 28.65M | 10.46M | 27.46M |
| Operating Income | -20.34M | -5.61M | 7.73M | -42.51M | -49.6M |
| Net Income | -24.52M | -12.76M | -62.9M | -41.54M | -46.05M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 138.98M | 172.33M | 151.28M | 144.41M | 191.55M |
| Total Liabilities | 71.51M | 110.46M | 102.47M | 111.93M | 121.78M |
| Total Equity | 67.47M | 61.86M | 48.82M | 32.48M | 69.77M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 10.51M | 11.21M | 132.94M | 115.53M | 172.33M |
| Total Liabilities | 84.96M | 77.62M | 5.82M | 29.72M | 110.46M |
| Total Equity | -74.46M | -66.41M | 127.12M | 85.81M | 61.86M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -17.38M | -33.54M | -16.17M | -35.27M | -53.42M |
| Investing | -27.98M | -17.39M | 14.79M | 14.66M | -16.69M |
| Financing | 23.46M | 28.46M | 1.22M | 16.55M | 81.31M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -23.74M | -1.94M | 10.44M | -18.72M | -33.54M |
| Investing | 3.23M | -33k | -15.52M | -36.72M | -17.39M |
| Financing | 4.94M | 2.74M | 113.11M | 8.35M | 28.46M |
| Market Cap | 414.73M |
| Price to Earnings Ratio | -9.01 |
| Price to Sales Ratio | 15.1 |
| Price to Cash Ratio | 9.63 |
| Price to Book Ratio | 6.7 |
| Dividend Yield | - |
| Shares Outstanding | 53.38M |
| Average Volume (1 week) | 304.88k |
| Average Volume (1 Month) | 393.66k |
| 52 Week Change | 26.34% |
| 52 Week High | 9.76 |
| 52 Week Low | 4.20 |
| Spread (Intraday) | 0.33 (4.16%) |
| Company Name | Zevra Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.kempharm.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
